VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
Real-time Estimate Cboe BZX  -  15:16 16/08/2022 BST
26.50 USD   -5.04%
08/10SECTOR UPDATE : Health Care Stocks Gain Pre-Bell Wednesday
MT
08/10SECTOR UPDATE : Health Care
MT
08/10Vir Biotechnology Swings to Q2 Net Loss, Posts Negative Revenue of $40.6 Million
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2022 08/11/2022 08/12/2022 08/15/2022 08/16/2022 Date
30.65(c) 27.85(c) 28.6(c) 27.9(c) 26.75 Last
2 630 441 1 580 151 1 420 535 1 348 246 82 725 Volume
+6.28% -9.14% +2.69% -2.45% -4.12% Change
More quotes
Estimated financial data (e)
Sales 2022 1 401 M - 1 160 M
Net income 2022 362 M - 300 M
Net cash position 2022 1 655 M - 1 370 M
P/E ratio 2022 10,4x
Yield 2022 -
Sales 2023 192 M - 159 M
Net income 2023 -477 M - -395 M
Net cash position 2023 1 229 M - 1 018 M
P/E ratio 2023 -7,40x
Yield 2023 -
Capitalization 3 701 M 3 701 M 3 064 M
EV / Sales 2022 1,46x
EV / Sales 2023 12,9x
Nbr of Employees 444
Free-Float 86,7%
More Financials
Company
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. It has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The Company's pipeline consists of... 
More about the company
Ratings of Vir Biotechnology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about VIR BIOTECHNOLOGY, INC.
08/10SECTOR UPDATE : Health Care Stocks Gain Pre-Bell Wednesday
MT
08/10SECTOR UPDATE : Health Care
MT
08/10Vir Biotechnology Swings to Q2 Net Loss, Posts Negative Revenue of $40.6 Million
MT
08/09VIR BIOTECHNOLOGY : Provides Corporate Update and Reports Second Quarter 2022 Financial Re..
PU
08/09VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
08/09Vir Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
08/09Vir Biotechnology Provides Corporate Update and ReportsáSecond Quarter 2022 Financial R..
GL
08/04VIR BIOTECHNOLOGY, INC. : Other Events (form 8-K)
AQ
07/21INSIDER SELL : Vir Biotechnology
MT
07/21Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial ..
GL
07/21Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial ..
AQ
07/14VIR BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/14Vir Biotechnology, Inc. Announces Resignation of Herbert Virgin as Executive Vice Presi..
CI
07/14Vir Biotechnology Announces Transition of Chief Scientific Officer
GL
07/14Vir Biotechnology Announces Transition of Chief Scientific Officer
GL
More news
News in other languages on VIR BIOTECHNOLOGY, INC.
08/10MISE À JOUR SECTORIELLE : Les actions du secteur de la santé gagnent avant la cloche mercr..
08/10MISE À JOUR SECTORIELLE : Soins de santé
08/10Vir Biotechnology subit une perte nette au deuxième trimestre et affiche un revenu néga..
08/09Vir Biotechnology, Inc. annonce ses résultats pour le deuxième trimestre et le semestre..
07/14Vir Biotechnology, Inc. annonce la démission de Herbert (Skip) Virgin en tant que vice-..
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 27,90 $
Average target price 52,29 $
Spread / Average Target 87,4%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Chief Accounting Officer
Vicki L. Sato Non-Executive Chairman
Phil Pang Chief Medical Officer
Herbert W. Virgin Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.-33.37%3 701
MODERNA, INC.-30.40%69 156
IQVIA HOLDINGS INC.-12.01%46 302
LONZA GROUP AG-25.21%44 721
SEAGEN INC.9.01%31 083
ALNYLAM PHARMACEUTICALS, INC.36.22%27 727